Coronary Artery DiseaseNCT05337319
Prospective Registry of the Current Status of Care for Patients With Coronary Artery Disease
An observational study of Coronary Artery Disease, run by Beijing Anzhen Hospital at 1 site in China.
Trial summary
The study will estimate the current status of care for participants with coronary artery disease Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease
- How many people
- 100,000 participants
- Where
- 1 siteChina
- Study dates
- 17 Jan 2022to 30 Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Hospitalized patients with coronary artery disease
Who may be able to join
- Hospitalized patients with discharge diagnosis as coronary artery disease (including atherosclerosis or non-athrosclerosis)
Who cannot join
- None
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Beijing Anzhen Hospital
Beijing
Chaoyang Wu, +86-10-64456214
About this study
Official title: A Multi-center, Prospective, Registry Study to Estimate the Current Status of Care for Patients With Coronary Artery Disease
The study will estimate the current status of care for participants with coronary artery disease
- Conditions
- Coronary Artery Disease
- Medical subject headings
- Coronary Artery Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
The overall composite of 10 performance measures for CAD care
Performance measures for CAD care including:
Proportion of patients received fibrinolytic therapy within 30 mins (STEMI) Proportion of patients received primary percutaneous coronary intervention within 90 mins (STEMI) Proportion of patients received reperfusion therapy (STEMI, high or moderate risk NSTE-ACS) Proportion of patients with aspirin prescribed at discharge Proportion of patients with P2Y12 inhibitors prescribed at discharge Proportion of patients with beta-blocker prescribed at discharge Proportion of patients with statin prescribed at discharge Proportion of left ventricular systolic dysfunction patients with ACEI or ARB prescribed at discharge Proportion of patients received evaluation of left ventricular systolic function Proportion of patients with a diagnosed non-obstructive coronary artery disease at discharge
Measured: Duration of hospital stay, an expected average of 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2022
- Study start17 Jan 2022
- Primary completion30 Dec 2027 (estimated)
- Study completion30 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- More trials run by Beijing Anzhen HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Anzhen Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shao-Ping Nie, Beijing Anzhen Hospital
- Investigators
- Shaoping Nie, MD, PhD, Principal investigator, Beijing Anzhen Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05337319
- Sponsor's protocol ID
- NCCMRC202201_001
- Status last verified
- May 2022
- First submitted
- 13 Apr 2022
- Last updated
- 26 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-center, Prospective, Registry Study to Estimate the Current Status of Care for Patients With Coronary Artery Disease
- ClinicalTrials.gov ID
- NCT05337319
- Acronym / sponsor ID
- NCCMRC202201_001
- Conditions
- Coronary Artery Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100,000 participants (estimated)
- Lead sponsor
- Beijing Anzhen HospitalUniversity, hospital or other
- Study start
- 17 Jan 2022 (actual)
- Primary completion
- 30 Dec 2027 (estimated)
- Study completion
- 30 Dec 2028 (estimated)
- First posted
- 20 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study will estimate the current status of care for participants with coronary artery disease
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Hospitalized patients with coronary artery disease
Key inclusion criteria (1 listed)
- Hospitalized patients with discharge diagnosis as coronary artery disease (including atherosclerosis or non-athrosclerosis)
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The overall composite of 10 performance measures for CAD care
Time frame: Duration of hospital stay, an expected average of 1 week
Performance measures for CAD care including: Proportion of patients received fibrinolytic therapy within 30 mins (STEMI) Proportion of patients received primary percutaneous coronary intervention within 90 mins (STEMI) Proportion of patients received reperfusion therapy (STEMI, high or moderate risk NSTE-ACS) Proportion of patients with aspirin prescribed at discharge Proportion of patients with P2Y12 inhibitors prescribed at discharge Proportion of patients with beta-blocker prescribed at discharge Proportion of patients with statin prescribed at discharge Proportion of left ventricular systolic dysfunction patients with ACEI or ARB prescribed at discharge Proportion of patients received evaluation of left ventricular systolic function Proportion of patients with a diagnosed non-obstructive coronary artery disease at discharge
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 May 2022.
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Shaoping Nie, MD, PhD principal investigator
Beijing Anzhen Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease, run by Beijing Anzhen Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shaoping Nie, MD, PhD (+86-10-84005255, spnie@ccmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The overall composite of 10 performance measures for CAD care (time frame: Duration of hospital stay, an expected average of 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2022.